Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bepotastine besilate/montelukast - Windlas Biotech

Next Previous
Drug Profile

Bepotastine besilate/montelukast - Windlas Biotech

Alternative Names: Bepotastine besilate/montelukast sodium - Windlas Biotech; Montelukast sodium/Bepotastine besilate - Windlas Biotech; Montelukast/bepotastine besilate - Windlas Biotech

Latest Information Update: 28 Oct 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Windlas Biotech
  • Class Acetates; Anti-inflammatories; Antiallergics; Antiasthmatics; Antidementias; Antihistamines; Antipruritics; Bronchodilators; Butyric acids; Chlorobenzenes; Eye disorder therapies; Neuroprotectants; Nootropics; Piperidines; Pyridines; Quinolines; Skin disorder therapies; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Leukotriene D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Allergic rhinitis

Most Recent Events

  • 28 Oct 2022 No recent reports of development identified for clinical-Phase-Unknown development in Allergic-rhinitis in India (PO, Tablet)
  • 01 Oct 2019 Windlas Biotech plans a phase III trials in Allergic rhinitis in India (PO, Tablet) in October 2019 (CTRI2019-09-021293)
  • 17 Sep 2019 Clinical trials in Allergic rhinitis in India (PO) before September 2019

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top